Catheter Precision Corporation (VTAK) - Multiplikator forward rega marang pendapatan

Catheter Precision revenues are based on the sale of electrophysiological mapping systems and catheter management. The forward price-to-sales ratio reflects the dynamics of this process, where 1.50 becomes the new value of the metric. Growth is supported by the implementation of VIVO 3D mapping and expansion into the EU. Meanwhile, Catheter Precision strictly adheres to RoHS standards, ensuring the sterility of medical instrument production.

The forward P/S ratio correlates the current market value of Catheter Precision (VTAK) with projected annual revenue, allowing for an assessment of the premium paid for future cash flows. By analyzing the projected P/S trend, an investor can determine the fairness of the valuation for a business whose financial growth depends on the demand for high-margin robotic catheters and VMAP arrhythmia mapping systems.